Get the Stockscreener App
0.00
100.00%
-93.80
After Hours:
2.65
2.65
+
Aerovate Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
See More
Previous Close:
$93.80
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$80.00M
Revenue:
-
Net Income/Loss:
$-75.52M
P/E Ratio:
0.00
EPS:
-2.88
Net Cash Flow:
$-56.92M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$105.00
Aerovate Therapeutics Inc Stock (AVTE) Company Profile
Name
Aerovate Therapeutics Inc
Sector
Industry
Phone
617-443-2400
Address
930 WINTER STREET, WALTHAM
Compare AVTE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTE
Aerovate Therapeutics Inc
|
0.00 | 80.00M | 0 | -75.52M | -56.92M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.48 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.13 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.53 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
767.00 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
351.13 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Aerovate Therapeutics Inc Stock (AVTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jun-16-25 | Upgrade | Guggenheim | Neutral → Buy |
| May-07-25 | Initiated | Wedbush | Outperform |
| May-05-25 | Initiated | Stifel | Buy |
| May-02-25 | Initiated | TD Cowen | Buy |
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Aerovate Therapeutics Inc Stock (AVTE) Latest News
Pulmonary Arterial Hypertension Market Expected to Gain Momentum Through 2034, According to DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros - Barchart.com
Head to Head Survey: Aerovate Therapeutics (NASDAQ:AVTE) vs. Vaccinex (NASDAQ:VCNX) - Defense World
Former Aerovate CCO Timothy Pigot Joins Inhibikase to Lead PAH Drug Commercialization Strategy - Stock Titan
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Shares Sold by XTX Topco Ltd - Defense World
Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Up 2.3% – Still a Buy? - Defense World
Aerovate Therapeutics (AVTE) Projected to Post Earnings on Monday - Defense World
Rhumbline Advisers Acquires 9,154 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Deep Track Capital, LP Acquires New Holdings in Aerovate Therapeutics Inc - GuruFocus
Pulmonary Arterial Hypertension Market Set to Grow Substantially Through 2034, DelveInsight Projects | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros - Barchart.com
Aerovate Therapeutics (NASDAQ:JBIO) Upgraded to Buy at Guggenheim - Defense World
Guggenheim Upgrades Jade Biosciences to Buy From Neutral, Price Target is $14 - MarketScreener
Guggenheim upgrades Jade Biosciences stock rating to Buy on transformation - Investing.com Canada
Aerovate Therapeutics (NASDAQ:JBIO) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Millennium Management LLC Cuts Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
FMR LLC's Strategic Acquisition of Aerovate Therapeutics Inc Shares - GuruFocus
19,564 Shares in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Purchased by Squarepoint Ops LLC - Defense World
Bank of America Corp DE Has $612,000 Stock Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Two Sigma Investments LP Cuts Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Two Sigma Advisers LP Grows Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Northern Trust Corp Purchases 6,296 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
BNP Paribas Financial Markets Makes New Investment in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jade Biosciences Secures Massive $300M Funding After Nasdaq Debut, First Clinical Trial Set for 2025 - Stock Titan
Aerovate Therapeutics (AVTE) to Release Earnings on Monday - Defense World
Renaissance Technologies LLC Buys 26,700 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target - marketscreener.com
Stifel initiates Jade Biosciences stock with a Buy, $19 target - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - marketscreener.com
Aerovate Therapeutics, Inc. Announces Board Changes - marketscreener.com
Aerovate Therapeutics Declares Special Cash Dividend In Connection With The Proposed Merger With Jade Biosciences - marketscreener.com
TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating - Investing.com
Aerovate Therapeutics Completes Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Announces Range of Expected Cash Dividend - marketscreener.com
Aerovate Therapeutics Announces Range Of Expected Cash Dividend - marketscreener.com
RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics - QuotedData
Jade Biosciences Highlights JADE-001 Progress in Presentation - TipRanks
Aerovate Therapeutics Inc (AVTE)’s financial ratios: A comprehensive overview - DWinneX
JBIO Stock Price and Chart — NASDAQ:JBIO - TradingView
Aerovate Therapeutics (AVTE) Options Set for Delisting | AVTE St - GuruFocus
Aerovate Therapeutics (AVTE) Options Set for Delisting | AVTE Stock News - GuruFocus
Traders Buy Large Volume of Call Options on Aerovate Therapeutics (NASDAQ:AVTE) - Defense World
Jade Biosciences closes merger with Aerovate Therapeutics - Coast Reporter
Aerovate Therapeutics Inc (AVTE) gets rating Downgrade from Wells Fargo - knoxdaily.com
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously ... - Bluefield Daily Telegraph
Jade Biosciences Completes Closing of Merger with Aerovate - GlobeNewswire
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million - Benzinga
Russell Investments Group Ltd. Boosts Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Aerovate Therapeutics, Inc. SEC 10-Q Report - TradingView
Aerovate Therapeutics Inc (AVTE) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Aerovate Therapeutics (AVTE) Soars 721.88% on Merger, Dividend News - AInvest
Aerovate Therapeutics Inc Stock (AVTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):